Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Amortization of Deferred Charges (2018 - 2025)

Historic Amortization of Deferred Charges for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to $518413.0.

  • Regenerative Medical Technology's Amortization of Deferred Charges rose 68457.08% to $518413.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 4386.48%. This contributed to the annual value of $2.1 million for FY2024, which is 3049.87% down from last year.
  • Regenerative Medical Technology's Amortization of Deferred Charges amounted to $518413.0 in Q3 2025, which was up 68457.08% from $4387.0 recorded in Q4 2024.
  • Regenerative Medical Technology's 5-year Amortization of Deferred Charges high stood at $1.0 million for Q2 2024, and its period low was $4387.0 during Q4 2024.
  • For the 5-year period, Regenerative Medical Technology's Amortization of Deferred Charges averaged around $491513.5, with its median value being $439102.0 (2022).
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first tumbled by 9942.59% in 2024, then skyrocketed by 68457.08% in 2025.
  • Quarter analysis of 5 years shows Regenerative Medical Technology's Amortization of Deferred Charges stood at $393621.0 in 2021, then increased by 11.01% to $436968.0 in 2022, then surged by 74.88% to $764156.0 in 2023, then tumbled by 99.43% to $4387.0 in 2024, then soared by 11717.03% to $518413.0 in 2025.
  • Its last three reported values are $518413.0 in Q3 2025, $4387.0 for Q4 2024, and $66076.0 during Q3 2024.